AbbVie Lowers Earnings Outlook After R&D Charge

AbbVie has revised its financial projections downwards for both the first quarter and the full fiscal year 2026. This adjustment follows a significant research and development charge amounting to $744 million. The substantial R&D investment indicates a strategic focus on pipeline development and innovation, but it has directly impacted the company's near-term profitability outlook. Investors will be closely monitoring the long-term benefits expected from these R&D expenditures as the company navigates this period of adjusted financial guidance.